3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide: Enabling Precision Research in Gastric Acid Secretion and Ulcer Models

Introduction & Principle: Unlocking the H+,K+-ATPase Signaling Pathway

Gastric acid secretion is a tightly regulated physiological process, with the H+,K+-ATPase enzyme—commonly known as the gastric proton pump—playing a central role. Dysregulation of this pathway underlies a spectrum of gastric acid-related disorders, including peptic ulcer disease and gastroesophageal reflux. The need for selective and potent H+,K+-ATPase inhibitors in bench research has led to the development and adoption of novel molecules such as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide (SKU: A2845), supplied by APExBIO.

This compound stands out for its dual role as a gastric acid secretion inhibitor and an antiulcer agent for research. With an IC₅₀ of 5.8 μM against H+,K+-ATPase and a remarkable 0.16 μM for suppression of histamine-induced acid formation, it offers high potency and specificity for elucidating the proton pump inhibition pathway and supporting antiulcer activity studies.

Experimental Workflow: Step-by-Step Integration into Peptic Ulcer Disease Models

1. Compound Preparation and Handling

• Solubility: The compound is insoluble in water and ethanol but dissolves at ≥17.27 mg/mL in DMSO. Prepare concentrated stock solutions in DMSO, aliquot immediately, and store at -20°C to preserve integrity.
• Purity Assurance: Each batch is verified by HPLC and NMR, with ≥98% purity—minimizing off-target effects in sensitive gastric acid secretion research assays.

2. In Vitro Assays for H+,K+-ATPase Activity

• Apply serial dilutions (0.01–100 μM) to gastric mucosal cell lines or isolated membrane preparations.
• Measure ATPase activity spectrophotometrically or via colorimetric phosphate release; include controls for DMSO vehicle and conventional inhibitors such as ic omeprazole for benchmarking.
• Quantify inhibition curves to determine IC₅₀ and compare directly with established proton pump inhibitors.

3. In Vivo Models: Peptic Ulcer Disease and Gastric Acid-Related Disorders

• Induce ulceration or hypersecretion in rodents via standard protocols (e.g., pylorus ligation, NSAID administration).
• Administer 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide at escalating doses (e.g., 0.1–10 mg/kg, dissolved in DMSO, diluted with saline as tolerated).
• Monitor gastric pH, acid output, and ulcer indices post-treatment. For mechanistic insights, pair with histamine or pentagastrin challenge to dissect pathway specificity.

Advanced Applications and Comparative Advantages

1. Dissecting the Proton Pump Inhibition Pathway
Unlike conventional agents, this compound exhibits potent inhibition not only of basal but also histamine-induced acid secretion—a key distinction highlighted in recent pharmacology reviews, where its selectivity is contrasted with broader-spectrum inhibitors. This enables precision mapping of the H+,K+-ATPase signaling pathway and refinement of antiulcer strategies in research settings.

2. Model Extension: From Ulcer to Gut–Brain Axis Studies
Recent research into neuroinflammation and the gut-liver-brain axis, such as the study by Kong et al. (2025), suggests that chronic liver and gastrointestinal pathologies are interconnected. While their primary focus was on neuroinflammation in hepatic encephalopathy, the experimental frameworks—using precise biochemical, behavioral, and imaging readouts—are complementary to advanced gastric acid and ulceration models. Integration of a selective gastric acid secretion inhibitor like A2845 could enhance the mechanistic resolution in studies that bridge gastrointestinal and neurological endpoints.

3. Superior Antiulcer Activity in Comparative Assays
Head-to-head experimental protocols with ic omeprazole and related agents reveal that 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide achieves comparable or superior ulcer protection at lower concentrations, with a rapid onset of action and minimal off-target cytotoxicity in vitro. This is attributable to its high binding affinity and kinetic profile, as delineated in both published resources and APExBIO data sheets.

Troubleshooting and Optimization Tips for Robust Results

• Solubility Challenges: If precipitation occurs upon dilution, ensure that DMSO stocks are fully dissolved before addition to aqueous buffers. For in vivo work, consider co-solvent approaches or fine-tuned dilution into warmed saline with gentle agitation.
• Stability Concerns: Avoid repeated freeze-thaw cycles. Prepare single-use aliquots and discard any solution stored for more than 24 hours to prevent degradation.
• Assay Interference: DMSO at concentrations above 0.5% can affect cell viability and enzyme activity. Titrate DMSO vehicle controls and minimize final concentration whenever possible.
• Comparative Controls: Always include ic omeprazole or other reference compounds to benchmark inhibition efficacy, especially when exploring novel antiulcer agent mechanisms or cross-validating pathway specificity.
• Batch-to-Batch Consistency: Use the same lot for all replicates within a study. Confirm purity and integrity with HPLC or NMR spot-checks when possible, especially for publication-critical data.

Future Outlook: Expanding the Scope of Gastric Acid Secretion Research

As research into peptic ulcer disease models and gastric acid-related disorders becomes increasingly sophisticated, the demand for highly selective, data-validated inhibitors grows. Integration of 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide into multi-omics workflows, such as those involving microbiome sequencing or metabolomics—akin to the analytical platforms in the Kong et al. (2025) study—will empower new discoveries across the gut–brain–liver axis.

Moreover, as discussed in the previously published resource, the mechanistic clarity provided by this compound extends and complements the broader pharmacology field, enabling researchers to unravel subtle regulatory mechanisms in proton pump inhibition beyond what is achievable with legacy compounds.

For researchers seeking to push the boundaries of antiulcer activity study and H+,K+-ATPase inhibitor pharmacology, sourcing from APExBIO ensures access to rigorously characterized, publication-grade molecules. Explore the full details and ordering options for 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide to advance your next experimental breakthrough.